The Microenvironment in Myeloproliferative Neoplasms.
Cytokines
Inflammation
Microenvironment
Myeloid cells
Myeloproliferative neoplasm
Prognosis
Journal
Hematology/oncology clinics of North America
ISSN: 1558-1977
Titre abrégé: Hematol Oncol Clin North Am
Pays: United States
ID NLM: 8709473
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
4
3
2022
Statut:
ppublish
Résumé
Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN. Although the neoplastic clone and their differentiated progeny drive the inflammatory process, they also induce ancillary cytokine secretion from nonmalignant cells. Here, the authors describe the inflammatory milieu in MPN based on soluble factors and cellular mediators. They also discuss the prognostic value of cytokine measurements in patients with MPN and potential therapeutic strategies that target the cellular players in inflammation.
Identifiants
pubmed: 33641864
pii: S0889-8588(20)30147-7
doi: 10.1016/j.hoc.2020.11.003
pmc: PMC8832361
mid: NIHMS1653929
pii:
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-216Subventions
Organisme : NCI NIH HHS
ID : P30 CA062203
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA077691
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009054
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP000414
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosures The authors declare that they have no conflict of interests. Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number T32CA009054. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Références
PLoS Med. 2006 Jul;3(7):e270
pubmed: 16834459
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
J Clin Oncol. 2011 Apr 1;29(10):1356-63
pubmed: 21300928
Circ Res. 2018 Jan 19;122(2):337-351
pubmed: 29348254
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643232
Nature. 2014 Aug 7;512(7512):78-81
pubmed: 25043017
Haematologica. 2011 Feb;96(2):315-8
pubmed: 21173097
Exp Hematol. 2014 May;42(5):360-8
pubmed: 24463275
Br J Cancer. 2013 Jun 11;108(11):2390-8
pubmed: 23640394
Eur J Haematol. 1999 Jul;63(1):19-25
pubmed: 10414450
Proc Natl Acad Sci U S A. 2010 Sep 7;107(36):15880-5
pubmed: 20798043
Blood. 2000 Dec 15;96(13):4261-6
pubmed: 11110700
Nature. 2019 Jul;571(7765):355-360
pubmed: 31270458
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Hemasphere. 2020 May 21;4(3):e371
pubmed: 32647796
J Exp Med. 2016 Aug 22;213(9):1723-40
pubmed: 27481130
Haematologica. 2010 Jul;95(7):1216-20
pubmed: 20053870
Am J Hematol. 2012 Nov;87(11):1003-5
pubmed: 22965887
Blood. 2015 Aug 20;126(8):972-82
pubmed: 26022238
Blood. 2011 Dec 8;118(24):6392-8
pubmed: 21860020
Oncogene. 2011 Feb 24;30(8):990-1001
pubmed: 21042281
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Cytokine. 2002 Nov 24;20(4):178-83
pubmed: 12543083
Toxins (Basel). 2013 Feb 18;5(2):336-62
pubmed: 23430540
Cancer Med. 2018 Nov;7(11):5796-5802
pubmed: 30318865
J Cell Mol Med. 2018 Aug;22(8):4005-4011
pubmed: 29975001
Cancer Epidemiol. 2014 Feb;38(1):56-61
pubmed: 24275260
Hematol Transfus Cell Ther. 2018 Apr-Jun;40(2):120-131
pubmed: 30057985
Blood. 2006 Nov 15;108(10):3472-6
pubmed: 16868251
Cell Stem Cell. 2017 Jun 1;20(6):785-800.e8
pubmed: 28457748
Leuk Res. 2007 Oct;31(10):1389-92
pubmed: 17328948
Tumori. 2009 May-Jun;95(3):404-5
pubmed: 19688988
Br J Haematol. 2005 Sep;130(5):709-15
pubmed: 16115126
Nat Cell Biol. 2020 Jun;22(6):716-727
pubmed: 32367047
Blood Adv. 2020 Jan 28;4(2):312-321
pubmed: 31978215
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Front Immunol. 2019 Jun 14;10:1373
pubmed: 31258539
Blood. 2014 Nov 6;124(19):2996-3006
pubmed: 25217696
Leukemia. 2019 Aug;33(8):1978-1995
pubmed: 30718771
Int J Cancer. 2014 Apr 1;134(7):1741-50
pubmed: 24114627
Cancer Discov. 2015 Mar;5(3):316-31
pubmed: 25572172
Am J Hematol. 2009 Feb;84(2):102-8
pubmed: 19105233
Cancer Res. 2015 Nov 15;75(22):4753-65
pubmed: 26404004
Blood Adv. 2019 Jan 22;3(2):122-131
pubmed: 30647074
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
Cell Immunol. 2012 Jul-Aug;278(1-2):91-4
pubmed: 23121980
Hemasphere. 2020 Jan 03;4(1):e327
pubmed: 32072143
Nat Cell Biol. 2017 Jun;19(6):677-688
pubmed: 28481328
Mol Cell. 2020 May 7;78(3):477-492.e8
pubmed: 32386542
Blood. 2008 Jul 1;112(1):141-9
pubmed: 18451306
Cell Stem Cell. 2013 Sep 5;13(3):285-99
pubmed: 23850243
Leukemia. 2018 Oct;32(10):2266-2270
pubmed: 29568096
Blood. 2007 Aug 1;110(3):986-93
pubmed: 17473062
Exp Hematol. 2005 May;33(5):523-30
pubmed: 15850829
Blood. 2018 Aug 30;132(9):973-976
pubmed: 29991558
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187